Regulatory approval

Published by the Health Service Executive. Approved

For the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.

This is written in the approval document.

Reimbursement

CDS

Citation

Brigatinib Therapy, 2021, version number 3, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6895/562_v3_brigatinib.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	v::ALK	Non-Small Cell Lung Cancer	Brigatinib